Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes

Published on 04 Jun 2025
Last Updated on 04 Jun 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended finerenone for inclusion on the MOH List of Subsidised Drugs as an add-on to standard of care for treating adults with chronic kidney disease and albuminuria associated with type 2 diabetes. This decision was based on finerenone being unlikely to represent an acceptable use of healthcare resources at the price proposed by the company.

Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes (Published 4 Jun 2025)

PES_Finerenone for treating chronic kidney disease and protein in the urine associated with type 2 diabetes (Published 4 Jun 2025)